TABLE 2.

Susceptibility of P. aeruginosa isolates to antimicrobial agents according to patient age (data from 1999 to 2002 combined)

Antimicrobial agent(s)Patient age (yr)Total no. of isolates% Sa% Ia% Ra
Amikacin18-398,47976.77.216.2
40-495,11390.73.95.4
50-596,51291.53.84.8
60-697,08692.43.83.8
≥7015,77893.73.33.0
Cefepime18-398,47972.814.113.1
40-495,11376.114.09.8
50-596,51274.614.411.0
60-697,08674.815.110.0
≥7015,77879.412.77.9
Ceftazidime18-398,47977.97.214.8
40-495,11377.58.414.1
50-596,51274.89.315.9
60-697,08675.410.014.6
≥7015,77878.010.511.5
Ciprofloxacin18-398,47955.810.533.7
40-495,11359.77.333.0
50-596,51258.37.634.1
60-697,08661.75.632.7
≥7015,77861.45.932.7
Gentamicin18-398,47961.211.127.7
40-495,11372.99.617.5
50-596,51273.18.118.8
60-697,08675.28.816.0
≥7015,77875.210.114.6
Imipenem18-398,47977.96.016.1
40-495,11376.75.417.9
50-596,51276.57.016.5
60-697,08676.07.216.8
≥7015,77881.16.911.9
Piperacillin18-398,47982.7-b17.3
40-495,11383.0-17.0
50-596,51280.7-19.3
60-697,08682.2-17.8
≥7015,77885.6-14.4
Piperacillin-tazobactam18-398,47987.6-12.4
40-495,11388.1-11.9
50-596,51286.5-13.5
60-697,08687.0-13.0
≥7015,77890.4-9.6
Ticarcillin-clavulanate18-398,47971.3-28.7
40-495,11368.2-31.8
50-596,51264.7-35.3
60-697,08665.7-34.3
≥7015,77869.9-30.1
Tobramycin18-398,47980.04.016.0
40-495,11385.91.612.5
50-596,51284.31.614.1
60-697,08686.91.511.7
≥7015,77887.61.610.7
  • a The percentages of susceptible (S), intermediate (I), and resistant (R) isolates according to NCCLS breakpoints are shown.

  • b -, NCCLS breakpoints for the intermediate category unavailable.